<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">NCP</journal-id>
<journal-id journal-id-type="hwp">spncp</journal-id>
<journal-id journal-id-type="nlm-ta">Nutr Clin Pract</journal-id>
<journal-title>Nutrition in Clinical Practice</journal-title>
<issn pub-type="ppub">0884-5336</issn>
<issn pub-type="epub">1941-2452</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0884533612475133</article-id>
<article-id pub-id-type="publisher-id">10.1177_0884533612475133</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>CAM Corner</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Use of Complementary and Alternative Medicine for Liver Disease</article-title>
<subtitle>Part II</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Mullin</surname><given-names>Gerard E.</given-names></name>
<degrees>MD</degrees>
</contrib>
<aff id="aff1-0884533612475133">The Johns Hopkins Hospital, Baltimore, Maryland</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0884533612475133">Gerard E. Mullin, The Johns Hopkins Hospital, 600 N. Wolfe St, Carnegie 464, Baltimore, MD 21205, USA. Email: <email>gmullin1@jhmi.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>2</issue>
<issue-title>Research and Publishing</issue-title>
<fpage>277</fpage>
<lpage>279</lpage>
<permissions>
<copyright-statement>© 2013 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Herbal and dietary supplement hepatotoxicity is one of the most concerning aspects of complementary and alternative medicine (CAM) utilization. The April/May 2013 issue of CAM Corner is dedicated to nutraceutical-related hepatotoxicity.</p>
<sec id="section1-0884533612475133">
<title>Herbal and Nutraceutical Hepatotoxicity</title>
<sec id="section2-0884533612475133">
<title>Prevalence and Common Culprits</title>
<p>In the United States and Europe, herbal products are implicated as a cause of hepatotoxicity in &lt;10% of patients with drug-induced liver injury and drug-induced acute liver failure (ALF).<sup><xref ref-type="bibr" rid="bibr1-0884533612475133">1</xref>,<xref ref-type="bibr" rid="bibr2-0884533612475133">2</xref></sup> However, a relatively high incidence of hepatotoxicity has been reported in Korea (73%) and Singapore (71%).<sup><xref ref-type="bibr" rid="bibr3-0884533612475133">3</xref></sup> A recent review of the literature revealed that 60 different herbal products have been reported to cause hepatotoxicity. The authors noted that causality was likely for Ayurvedic herbs, chaparral, Chinese herbal mixture, comfrey, germander, greater celandine, green tea, a few Herbalife products, Jin Bu Huan, kava, Ma Huang, mistletoe, senna, Syosaiko-to, and Venencapsan.<sup><xref ref-type="bibr" rid="bibr4-0884533612475133">4</xref></sup></p>
</sec>
<sec id="section3-0884533612475133">
<title>Eastern-Based Herbals</title>
<p>Despite its proven causality, Ayurvedic medications have rarely been associated with hepatotoxicity, whereas traditional Chinese medicines (TCM) are more notorious culprits. Examples of hepatotoxic TCM preparations include Jin Bu Huan (sedative, analgesic), Ma Huang (<italic>Ephedra sinica</italic> nasal decongestant and bronchodilator), TJ 19 (used for liver ailments), geniposide (febrile conditions), <italic>Paeonia</italic> spp (eczema), and <italic>Polygonum multiflorum</italic>.<sup><xref ref-type="bibr" rid="bibr5-0884533612475133">5</xref><xref ref-type="bibr" rid="bibr6-0884533612475133"/><xref ref-type="bibr" rid="bibr7-0884533612475133"/>-<xref ref-type="bibr" rid="bibr8-0884533612475133">8</xref></sup> Green tea is very popular worldwide and is also a frequent ingredient in various dietary supplements used predominantly for weight loss. There are several reports of hepatotoxicity following the ingestion of numerous and different green tea preparations, including ALF.<sup><xref ref-type="bibr" rid="bibr9-0884533612475133">9</xref></sup></p>
</sec>
<sec id="section4-0884533612475133">
<title>Germander</title>
<p>Germander (<italic>Teucrium chamaedrys</italic>), an aromatic plant that is native to many parts of Europe, the Greek Islands, and Syria, has an ancient reputation as a cure for gout. Emperor Charles V is said to have been cured of gout with this remedy. Many reports of liver injury have been documented, and these include presentations as acute and chronic hepatitis and as ALF.<sup><xref ref-type="bibr" rid="bibr10-0884533612475133">10</xref></sup></p>
</sec>
<sec id="section5-0884533612475133">
<title>Greater Celandine</title>
<p>Greater celandine (<italic>Chelidonium majus</italic>), a plant found mainly in Europe, is rich in alkaloids and has been approved for use in Germany to treat spastic disorders of the bile ducts and gastrointestinal tract such as irritable bowel syndrome (IBS). Greater celandine is a component of Iberogast, which is a popular remedy for IBS in Europe and has evidence to show efficacy for IBS and nonulcer dyspepsia.<sup><xref ref-type="bibr" rid="bibr11-0884533612475133">11</xref></sup> In 2005, the German regulatory agency received 43 reports of hepatotoxicity from greater celandine, and 16 cases were confirmed.<sup><xref ref-type="bibr" rid="bibr12-0884533612475133">12</xref></sup> The hepatotoxicity associated with germander occurs after an average of 9 weeks of ingestion and appears clinically as jaundice, elevated hepatic transaminases, periportal inflammation, and centribular necrosis. Generally, the syndrome resolves itself when germander is discontinued.<sup><xref ref-type="bibr" rid="bibr13-0884533612475133">13</xref></sup></p>
</sec>
<sec id="section6-0884533612475133">
<title>Kava</title>
<p>Kava (<italic>Piper methysticum</italic>) is a plant indigenous to the South Pacific islands. In Western countries, dietary supplements containing kava are promoted as an agent to relieve stress, anxiety, and tension, as well as for sleeplessness and menopausal symptoms.<sup><xref ref-type="bibr" rid="bibr14-0884533612475133">14</xref>,<xref ref-type="bibr" rid="bibr15-0884533612475133">15</xref></sup> Kava hepatotoxicity may occur after daily doses of 45–1200 mg kavapyrones and a therapy ranging between 1 week and 24 months.<sup><xref ref-type="bibr" rid="bibr16-0884533612475133">16</xref></sup> Kava hepatotoxicity is the result of an idiosyncratic reaction of the metabolic rather than the immunologic type. Those using an alcoholic or acetonic extract are at particular risk for overmedication and severe hepatotoxicity. Comedication is a risk factor for the development of kava hepatotoxicity. Kava treatment, widely beyond regulatory recommendations, may be associated with the risk for life-threatening ALF requiring liver transplantation.</p>
</sec>
<sec id="section7-0884533612475133">
<title>Pennyroyal</title>
<p>Pennyroyal (<italic>Mentha pulegium</italic>), along with other plants frequently mentioned in ancient Greek medical writings, had a special role in the Eleusinian Mysteries, rites dedicated to the earth goddess Demeter and her daughter Persephone. Although various physical means of contraception were employed by the Greeks, ancient physicians had plant-based prescriptions for both abortion and contraception.<sup><xref ref-type="bibr" rid="bibr17-0884533612475133">17</xref></sup> Pennyroyal is an herb that has long been used as an abortifacient despite its potentially lethal hepatotoxic and neurotoxic effects.<sup><xref ref-type="bibr" rid="bibr18-0884533612475133">18</xref></sup></p>
</sec>
<sec id="section8-0884533612475133">
<title>Pyrrolizidine Alkaloids</title>
<p>The most notorious herbal constituents that cause the most fatal liver injury are pyrrolizidine alkaloids (PAs). Botanicals containing PAs were first associated with hepatotoxicity more than 70 years ago. These alkaloids have been long regarded as causing lethal hepatotoxicity. PAs can be found in more than 350 plant species but are typically in plants from the genera <italic>Crotalaria, Heliotropium, Senecio</italic>, and <italic>Symphytum</italic> (the genus of the formerly popular herb comfrey). Human exposure to PAs typically occurs from teas, contaminated foods, or herbal preparations. Because of the PAs found in comfrey, companies have been advised by the Food and Drug Administration (FDA) to remove products for internal consumption from the market.<sup><xref ref-type="bibr" rid="bibr19-0884533612475133">19</xref></sup> The first reports of PA causing fatal hepatotoxicity were reported in Jamaican children drinking bush tea. The pattern of liver injury is acute or chronic veno-occlusive disease (VOD). There are 3 possible outcomes for acute hepatic VOD from PA: fulminant hepatic failure with 15%–20% fatality, complete recovery in 50%, or a protracted course of chronic liver disease (CLD).<sup><xref ref-type="bibr" rid="bibr20-0884533612475133">20</xref></sup> It is possible for PA to have a subacute insidious presentation that gradually leads to CLD.</p>
</sec>
<sec id="section9-0884533612475133">
<title>Herbalife</title>
<p>Herbalife products are distributed as herbal and dietary supplements for weight control among other unconfirmed health claims. Herbalife is one of the largest weight management and nutrition supplement companies in the world, with annual sales of more than $3 billion.<sup><xref ref-type="bibr" rid="bibr21-0884533612475133">21</xref></sup> There are several published reports of Herbalife hepatotoxicity<sup><xref ref-type="bibr" rid="bibr22-0884533612475133">22</xref></sup> from <italic>Solidago gigantea, Ilex paraguariensis, Petroselinum crispum, Garcinia cambogia, Spiraea, Matricaria chamomilla, Liquiritiae, Foeniculum amare, Humulus lupulus</italic>, chromium, and numerous other ingredients. The precise mechanism or the responsible agent in the products is uncertain.<sup><xref ref-type="bibr" rid="bibr23-0884533612475133">23</xref></sup></p>
</sec>
<sec id="section10-0884533612475133">
<title>Hydroxycut</title>
<p>Hydroxycut is another popular dietary supplement consisting of a variety of herbal mixtures that claim to enhance the ability to lose weight. Several cases of hepatotoxicity associated with Hydroxycut have been reported. <italic>Camellia sinensis, Gymnema sylvestre, Amorphophallus konjac, Paullinia cupana, Garcinia cambogia</italic>, caffeine, α-lipoic acid, L-carnitine, calcium, potassium, and chromium are listed as active ingredients. The responsible toxic ingredient is not entirely certain but may be the consequence of <italic>C sinensis</italic> present in the product.<sup><xref ref-type="bibr" rid="bibr24-0884533612475133">24</xref></sup> Hydroxycut was withdrawn by its manufacturer after a May 1, 2009, warning issued by the FDA for its possible role in 23 cases of hepatotoxicity.<sup><xref ref-type="bibr" rid="bibr25-0884533612475133">25</xref></sup></p>
<p>Obesity continues to be a major healthcare problem in the United States, and adult Americans spend over $30 billion a year in weight loss products and services.<sup><xref ref-type="bibr" rid="bibr26-0884533612475133">26</xref></sup> Nonconventional products (“natural products”) continue to be touted as “safe and effective” for treatment of various health conditions, including weight reduction. However, these products have not undergone rigorous scrutiny for effectiveness and safety, and consequently, drug-induced toxicities do occur with some frequency. Although some preparations of Hydroxycut have been withdrawn and others placed back on the market by its manufacturer, a substantial number of similar products still remain on the market that may have deleterious health effects.</p>
</sec>
<sec id="section11-0884533612475133">
<title>Niacin</title>
<p>Niacin, or nicotinic acid, is used primarily to increase high-density lipoprotein through a mechanism that is not entirely clear. A reduction in low-density lipoprotein (LDL) is also seen and apparently occurs due to an inhibition of hepatic very low-density lipoprotein and triglyceride secretion and thus a reduction in the substrate needed to make LDL particles.<sup><xref ref-type="bibr" rid="bibr27-0884533612475133">27</xref></sup> The sustained-released (SR) preparation is easily available over the counter and may be used by patients seeking a perceived naturopathic solution to their high cholesterol or by patients seeking a cheaper option to treat themselves. Patients may possibly be using potentially toxic doses without the prior knowledge of their physicians. It is this unsupervised use of the SR formulation that often leads to the dose-related toxicity of niacin and should be discouraged. The onset of hepatotoxicity generally appears anywhere from 1 week to 48 months after the initiation of the drug and usually subsides with discontinuation in 1 to 2 months.<sup><xref ref-type="bibr" rid="bibr28-0884533612475133">28</xref></sup> Fulminant hepatic failure has been reported but is very rare.<sup><xref ref-type="bibr" rid="bibr29-0884533612475133">29</xref></sup> Combination therapy with statins does not increase the incidence of adverse effects of either medication.</p>
</sec>
</sec>
<sec id="section12-0884533612475133" sec-type="conclusions">
<title>Conclusions</title>
<p>Herbs and nutraceutical use have proven benefits; however, consumers need to be aware of the potential adverse effects. Some of the most profound toxicity occurs in the liver. We have reviewed the most dangerous herbs that can cause severe liver damage. Dozens of other herbs have been shown to cause liver injury. Monitoring of liver chemistries for those who report ingesting herbs with known hepatotoxicity is prudent.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: None declared.</p>
</fn>
<fn fn-type="other">
<p>This article originally appeared online on February 14, 2013.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0884533612475133">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andrade</surname><given-names>RJ</given-names></name>
<name><surname>Lucena</surname><given-names>MI</given-names></name>
<name><surname>Fernandez</surname><given-names>MC</given-names></name>
<etal/>
</person-group>. <article-title>Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period</article-title>. <source>Gastroenterology</source>. <year>2005</year>;<volume>129</volume>:<fpage>512</fpage>-<lpage>521</lpage>.</citation>
</ref>
<ref id="bibr2-0884533612475133">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Russo</surname><given-names>MW</given-names></name>
<name><surname>Galanko</surname><given-names>JA</given-names></name>
<name><surname>Shrestha</surname><given-names>R</given-names></name>
<name><surname>Fried</surname><given-names>MW</given-names></name>
<name><surname>Watkins</surname><given-names>P</given-names></name>
</person-group>. <article-title>Liver transplantation for acute liver failure from drug induced liver injury in the United States</article-title>. <source>Liver Transpl</source>. <year>2004</year>;<volume>10</volume>:<fpage>1018</fpage>-<lpage>1023</lpage>.</citation>
</ref>
<ref id="bibr3-0884533612475133">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suk</surname><given-names>KT</given-names></name>
<name><surname>Kim</surname><given-names>DJ</given-names></name>
<name><surname>Kim</surname><given-names>CH</given-names></name>
<etal/>
</person-group>. <article-title>A prospective nationwide study of drug-induced liver injury in Korea</article-title>. <source>Am J Gastroenterol</source>. <year>2012</year>;<volume>107</volume>:<fpage>1380</fpage>-<lpage>1387</lpage>.</citation>
</ref>
<ref id="bibr4-0884533612475133">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Teschke</surname><given-names>R</given-names></name>
<name><surname>Wolff</surname><given-names>A</given-names></name>
<name><surname>Frenzel</surname><given-names>C</given-names></name>
<name><surname>Schulze</surname><given-names>J</given-names></name>
<name><surname>Eickhoff</surname><given-names>A</given-names></name>
</person-group>. <article-title>Herbalife® hepatotoxicity: a tabular compilation of reported cases</article-title>. <source>Liver Int</source>. <year>2012</year>;<volume>32</volume>(<issue>10</issue>): <fpage>1543</fpage>-<lpage>1556</lpage>.</citation>
</ref>
<ref id="bibr5-0884533612475133">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hsu</surname><given-names>LM</given-names></name>
<name><surname>Huang</surname><given-names>YS</given-names></name>
<name><surname>Tsay</surname><given-names>SH</given-names></name>
<name><surname>Chang</surname><given-names>FY</given-names></name>
<name><surname>Lee</surname><given-names>SD</given-names></name>
</person-group>. <article-title>Acute hepatitis induced by Chinese hepatoprotective herb, xiao-chai-hu-tang</article-title>. <source>J Chin Med Assoc</source>. <year>2006</year>;<volume>69</volume>:<fpage>86</fpage>-<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr6-0884533612475133">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kamiyama</surname><given-names>T</given-names></name>
<name><surname>Nouchi</surname><given-names>T</given-names></name>
<name><surname>Kojima</surname><given-names>S</given-names></name>
<name><surname>Murata</surname><given-names>N</given-names></name>
<name><surname>Ikeda</surname><given-names>T</given-names></name>
<name><surname>Sato</surname><given-names>C</given-names></name>
</person-group>. <article-title>Autoimmune hepatitis triggered by administration of an herbal medicine</article-title>. <source>Am J Gastroenterol</source>. <year>1997</year>;<volume>92</volume>:<fpage>703</fpage>-<lpage>704</lpage>.</citation>
</ref>
<ref id="bibr7-0884533612475133">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hiramatsu</surname><given-names>K</given-names></name>
<name><surname>Sakata</surname><given-names>H</given-names></name>
<name><surname>Horita</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Mesenteric phlebosclerosis associated with long-term oral intake of geniposide, an ingredient of herbal medicine</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2012</year>;<volume>36</volume>:<fpage>575</fpage>-<lpage>586</lpage>.</citation>
</ref>
<ref id="bibr8-0884533612475133">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Galloway</surname><given-names>JH</given-names></name>
<name><surname>Marsh</surname><given-names>ID</given-names></name>
<name><surname>Bittiner</surname><given-names>SB</given-names></name>
<etal/>
</person-group>. <article-title>Chinese herbs for eczema, the active compound?</article-title> <source>Lancet</source>. <year>1991</year>;<volume>337</volume>:<fpage>566</fpage>.</citation>
</ref>
<ref id="bibr9-0884533612475133">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mazzanti</surname><given-names>G</given-names></name>
<name><surname>Menniti-Ippolito</surname><given-names>F</given-names></name>
<name><surname>Moro</surname><given-names>PA</given-names></name>
<etal/>
</person-group>. <article-title>Hepatotoxicity from green tea: a review of the literature and two unpublished cases</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2009</year>;<volume>65</volume>:<fpage>331</fpage>-<lpage>341</lpage>.</citation>
</ref>
<ref id="bibr10-0884533612475133">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seeff</surname><given-names>LB</given-names></name>
</person-group>. <article-title>Herbal hepatotoxicity</article-title>. <source>Clin Liver Dis</source>. <year>2007</year>;<volume>11</volume>:<fpage>577</fpage>-<lpage>596</lpage>.</citation>
</ref>
<ref id="bibr11-0884533612475133">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ammon</surname><given-names>HP</given-names></name>
<name><surname>Kelber</surname><given-names>O</given-names></name>
<name><surname>Okpanyi</surname><given-names>SN</given-names></name>
</person-group>. <article-title>Spasmolytic and tonic effect of Iberogast (STW 5) in intestinal smooth muscle</article-title>. <source>Phytomedicine</source>. <year>2006</year>;<volume>13</volume>(<supplement>suppl 5</supplement>):<fpage>114</fpage>-<lpage>121</lpage>.</citation>
</ref>
<ref id="bibr12-0884533612475133">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>BenniTeschke</surname><given-names>R</given-names></name>
<name><surname>Glass</surname><given-names>X</given-names></name>
<name><surname>Schulze</surname><given-names>J</given-names></name>
</person-group>. <article-title>Herbal hepatotoxicity by greater celandine (<italic>Celidonium majus</italic>): causality assessment of 22 spontaneous reports</article-title>. <source>Regul Toxicol Pharmacol</source>. <year>2011</year>;<volume>61</volume>(<issue>3</issue>):<fpage>282</fpage>-<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr13-0884533612475133">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brent</surname><given-names>J</given-names></name>
</person-group>. <article-title>Three new herbal hepatotoxic syndromes</article-title>. <source>Clin Toxicol</source>. <year>1999</year>;<volume>37</volume>(<issue>6</issue>): <fpage>715</fpage>-<lpage>719</lpage>.</citation>
</ref>
<ref id="bibr14-0884533612475133">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Teschke</surname><given-names>R</given-names></name>
</person-group>. <article-title>Kava hepatotoxicity: pathogenetic aspects and prospective considerations</article-title>. <source>Liver Int</source>. <year>2010</year>;<volume>30</volume>:<fpage>1270</fpage>-<lpage>1279</lpage>.</citation>
</ref>
<ref id="bibr15-0884533612475133">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pittler</surname><given-names>MH</given-names></name>
<name><surname>Edzard</surname><given-names>E</given-names></name>
</person-group>. <article-title>Kava extract for treating anxiety</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2001</year>;(<issue>4</issue>):<fpage>CD003383</fpage>.</citation>
</ref>
<ref id="bibr16-0884533612475133">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Teschke</surname><given-names>R</given-names></name>
<name><surname>Schwarzenboeck</surname><given-names>A</given-names></name>
<name><surname>Hennermann</surname><given-names>K-H</given-names></name>
</person-group>. <article-title>Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases</article-title>. <source>Eur J Gastroenterol Hepatol</source>. <year>2008</year>;<volume>20</volume>:<fpage>1182</fpage>-<lpage>1193</lpage>.</citation>
</ref>
<ref id="bibr17-0884533612475133">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nelson</surname><given-names>SE</given-names></name>
</person-group>. <article-title>Persephone’s seeds: abortifacients and contraceptives in ancient Greek medicine and their recent scientific appraisal</article-title>. <source>Pharm Hist</source>. <year>2009</year>;<volume>51</volume>(<issue>2</issue>):<fpage>57</fpage>-<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr18-0884533612475133">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>IB</given-names></name>
<name><surname>Mullen</surname><given-names>WH</given-names></name>
<name><surname>Meeker</surname><given-names>JE</given-names></name>
<etal/>
</person-group>. <article-title>Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature</article-title>. <source>Ann Intern Med</source>. <year>1996</year>;<volume>124</volume>:<fpage>726</fpage>-<lpage>734</lpage>.</citation>
</ref>
<ref id="bibr19-0884533612475133">
<label>19.</label>
<citation citation-type="gov">
<person-group person-group-type="author">
<name><surname>Lewis</surname><given-names>CJ</given-names></name>
</person-group>. <article-title>FDA advises dietary supplement manufacturers to remove comfrey products from the market [letter to industry trade organizations, professional organizations, and nonprofit groups]</article-title>. <month>July</month> <day>6</day>, <year>2001</year>. <ext-link ext-link-type="uri" xlink:href="http://www.cfsan.fda.gov/~dms/dspltr06.html">http://www.cfsan.fda.gov/~dms/dspltr06.html</ext-link></citation>
</ref>
<ref id="bibr20-0884533612475133">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Z</given-names></name>
<name><surname>Huo</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Hepatic veno-occulsive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations</article-title>. <source>Neth J Med</source>. <year>2010</year>;<volume>68</volume>(<issue>6</issue>):<fpage>252</fpage>-<lpage>260</lpage>.</citation>
</ref>
<ref id="bibr21-0884533612475133">
<label>21.</label>
<citation citation-type="web">
<collab>Herbalife</collab>. <ext-link ext-link-type="uri" xlink:href="http://company.herbalife.com/Content/en-US/pdf/about-herbalife/press-room/Herbalife-Corporate-Profile-October-2009.pdf">http://company.herbalife.com/Content/en-US/pdf/about-herbalife/press-room/Herbalife-Corporate-Profile-October-2009.pdf</ext-link></citation>
</ref>
<ref id="bibr22-0884533612475133">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jóhannsson</surname><given-names>M</given-names></name>
<name><surname>Ormarsdóttir</surname><given-names>S</given-names></name>
<name><surname>Olafsson</surname><given-names>S</given-names></name>
</person-group>. <article-title>Hepatotoxicity associated with Herbalife® products</article-title>. <source>Laeknabladid</source>. <year>2010</year>;<volume>96</volume>(<issue>3</issue>):<fpage>167</fpage>-<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr23-0884533612475133">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Appelhans</surname><given-names>K</given-names></name>
<name><surname>Smith</surname><given-names>C</given-names></name>
<name><surname>Bejar</surname><given-names>E</given-names></name>
<name><surname>Henig</surname><given-names>YS</given-names></name>
</person-group>. <article-title>Revisiting acute liver injury associated with Herbalife products</article-title>. <source>World J Hepatol</source>. <year>2011</year>;<volume>3</volume>: <fpage>275</fpage>-<lpage>277</lpage>.</citation>
</ref>
<ref id="bibr24-0884533612475133">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fong</surname><given-names>TL</given-names></name>
<name><surname>Klontz</surname><given-names>KC</given-names></name>
<name><surname>Canas-Coto</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Hepatotoxicity due to Hydroxycut: a case series</article-title>. <source>Am J Gastroenterol</source>. <year>2010</year>;<volume>105</volume>:<fpage>1561</fpage>-<lpage>1566</lpage>.</citation>
</ref>
<ref id="bibr25-0884533612475133">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stickel</surname><given-names>F</given-names></name>
<name><surname>Kessebohm</surname><given-names>K</given-names></name>
<name><surname>Weimann</surname><given-names>R</given-names></name>
<name><surname>Seitz</surname><given-names>HK</given-names></name>
</person-group>. <article-title>Review of liver injury associated with dietary supplements</article-title>. <source>Liver Int</source>. <year>2011</year>;<volume>31</volume>:<fpage>595</fpage>-<lpage>605</lpage>.</citation>
</ref>
<ref id="bibr26-0884533612475133">
<label>26.</label>
<citation citation-type="gov">
<person-group person-group-type="author">
<name><surname>Cleland</surname><given-names>RL</given-names></name>
<name><surname>Gross</surname><given-names>WC</given-names></name>
<name><surname>Koss</surname><given-names>LD</given-names></name>
<name><surname>Daynard</surname><given-names>M</given-names></name>
<name><surname>Muoio</surname><given-names>KM</given-names></name>
</person-group>. <article-title>Federal Trade Commission staff report Sept 2002: weight-loss advertising: an analysis of current trends</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.ftc.gov/bcp/reports/weightloss.pdf">http://www.ftc.gov/bcp/reports/weightloss.pdf</ext-link></citation>
</ref>
<ref id="bibr27-0884533612475133">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McCormack</surname><given-names>PL</given-names></name>
<name><surname>Keating</surname><given-names>GM</given-names></name>
</person-group>. <article-title>Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia</article-title>. <source>Drugs</source>. <year>2005</year>;<volume>65</volume>(<issue>18</issue>): <fpage>2719</fpage>-<lpage>2740</lpage>.</citation>
</ref>
<ref id="bibr28-0884533612475133">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Henkin</surname><given-names>Y</given-names></name>
<name><surname>Johnson</surname><given-names>KC</given-names></name>
<name><surname>Segrest</surname><given-names>JP</given-names></name>
</person-group>. <article-title>Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin</article-title>. <source>JAMA</source>. <year>1990</year>;<volume>264</volume>(<issue>2</issue>):<fpage>241</fpage>-<lpage>243</lpage>.</citation>
</ref>
<ref id="bibr29-0884533612475133">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mullin</surname><given-names>GE</given-names></name>
<name><surname>Greenson</surname><given-names>JK</given-names></name>
<name><surname>Mitchell</surname><given-names>MC</given-names></name>
</person-group>. <article-title>Fulminant hepatic failure after ingestion of sustained-release nicotinic acid</article-title>. <source>Ann Intern Med</source>. <year>1989</year>;<volume>111</volume>(<issue>3</issue>):<fpage>253</fpage>-<lpage>255</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>